USNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
USANA Health Sciences Inc (USNA) does not present a strong buy opportunity for a long-term beginner investor at this time. The technical indicators show a neutral to bearish trend, options data suggests mixed sentiment, and the company's financial performance has deteriorated significantly in the latest quarter. While there are positive news catalysts regarding product innovation and quality, these are not sufficient to offset the weak financials and lack of strong trading signals.
The MACD is positive and expanding, indicating slight bullish momentum. However, RSI is neutral at 44.007, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 17.393, with key support at 16.898 and resistance at 17.888. Overall, the technical outlook is neutral to bearish.
USANA's CellSentials supplement received the ConsumerLab.com Seal of Approval, highlighting product quality and innovation. The product addresses common nutrient deficiencies and includes patented ingredients for health benefits.
The company's financial performance in Q4 2025 showed a significant decline, with net income dropping by -139.85% YoY and EPS falling by -143.48% YoY. Gross margin also decreased by -4.62% YoY, indicating operational challenges.
In Q4 2025, revenue increased by 5.89% YoY to $226.2M. However, net income dropped to -$1.775M (-139.85% YoY), and EPS fell to -0.1 (-143.48% YoY). Gross margin declined to 78.16%, down -4.62% YoY, reflecting significant profitability issues.
No data on analyst ratings or price target changes is provided.
